πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 41 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8754218

Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives

TAKEDA GMBH Β· Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8703192

Dosage form containing pantoprazole as active ingredient

TAKEDA GMBH Β· Granted Tue Apr 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8663694

Taste masked dosage form containing roflumilast

TAKEDA GMBH Β· Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8648100

Roflumilast for the treatment of pulmonary hypertension

TAKEDA GMBH Β· Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8618142

Process for the preparation of roflumilast

TAKEDA GMBH Β· Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8609848

Pyrazolone-derivatives and their use as PDE-4 inhibitors

TAKEDA GMBH Β· Granted Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8604064

Process for the preparation of roflumilast

TAKEDA GMBH Β· Granted Tue Dec 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8541456

Roflumilast for the treatment of diabetes mellitus type 2

TAKEDA GMBH Β· Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8536206

Process for the preparation of roflumilast

TAKEDA GMBH Β· Granted Tue Sep 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8486923

Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhi

TAKEDA GMBH Β· Granted Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8481516

Ciclesonide containing sterile aqueous suspension

TAKEDA GMBH Β· Granted Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8465767

Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles

TAKEDA GMBH Β· Granted Tue Jun 18 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8455653

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

TAKEDA GMBH Β· Granted Tue Jun 04 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8445501

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

TAKEDA GMBH Β· Granted Tue May 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8440210

Stabilized pharmaceutical product

TAKEDA GMBH Β· Granted Tue May 14 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8435497

Formoterol of and ciclesonide combination

TAKEDA GMBH Β· Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8431154

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrroli

TAKEDA GMBH Β· Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted